{
    "clinical_study": {
        "@rank": "58769", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients in this arm will receive intravenous sterile saline 30 minutes before the gynecologic laparoscopy."
            }, 
            {
                "arm_group_label": "Cefazolin", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this arm will receive intravenous cephazolin 1g, 30 minutes before the gynecologic laparoscopy."
            }
        ], 
        "brief_summary": {
            "textblock": "Laparoscopy is a surgical procedure indicated for most gynecological pathologies and\n      presents numerous advantages over laparotomy, among them lower rates of surgical site\n      infection and less comorbidity feverish. Despite this, the use of antibiotic prophylaxis is\n      widely accepted and performed by most gynecologists. However, there isn't literature\n      evidence to support the routine use of antibiotics in the prophylaxis of wound infection on\n      laparoscopic pelvic surgery .Therefore, this study will evaluate the need for the use of\n      antibiotic prophylaxis in gynecological laparoscopies not including opening hollow viscera."
        }, 
        "brief_title": "Antibiotic Prophylaxis in Gynecologic Laparoscopy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Infection Secondary to Surgical Procedure", 
            "Surgical Site Infection"
        ], 
        "detailed_description": {
            "textblock": "It is a clinical, prospective, double-blind, randomized study. 114 women with gynecologic\n      disease, in which there is indication of laparoscopic surgical approach, will be\n      consecutively select. These women will be allocated in two arms, control and study, where\n      control group will use placebo and study will receive intravenous cephazolin. These patients\n      will be followed for 30 days according to Centers for Disease Control and Prevention\n      criteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with gynecologic disease, undergoing gynecologic laparoscopy without opening\n             hollow viscera.\n\n        Exclusion Criteria:\n\n          -  body mass index over 30 Kg/m2\n\n          -  smoking\n\n          -  diabetes type I or II with glycated hemoglobin exceeding 6.5%\n\n          -  patients who are at surgical risk classification of the American Society of\n             Anesthesiologists(ASA) as ASA III or higher\n\n          -  refusal to participate\n\n          -  postoperative antibiotic therapy for another indication clinical complication"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "114", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991834", 
            "org_study_id": "MPFabiola"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Placebo", 
                    "Cefazolin"
                ], 
                "description": "Gynecological laparoscopy without opening hollow viscera.", 
                "intervention_name": "gynecologic laparoscopy", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "pelvic laparoscopy", 
                    "gynecologic laparoscopic surgery"
                ]
            }, 
            {
                "arm_group_label": "Cefazolin", 
                "description": "Intravenous administration of 1 g of cefazolin", 
                "intervention_name": "Cefazolin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cephazolin", 
                    "Cefazoline", 
                    "Cephazolin Sodium for Injection", 
                    "Kefzol"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Intravenous administration of saline sterile solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "placebo treatment"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Cefazolin", 
                "Antibiotics, Antitubercular"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "gynecologic surgical procedures", 
            "laparoscopy", 
            "surgical wound infection", 
            "antibiotic prophylaxis"
        ], 
        "lastchanged_date": "November 29, 2013", 
        "location": [
            {
                "contact": {
                    "email": "silvaniavieira@mastercabo.com.br", 
                    "last_name": "Silvania CV Archangelo, MD, PhD", 
                    "phone": "553534235988"
                }, 
                "facility": {
                    "address": {
                        "city": "Pouso Alegre", 
                        "country": "Brazil", 
                        "state": "Minas Gerais", 
                        "zip": "37550-000"
                    }, 
                    "name": "Hospital das Clinicas Samuel Libanio"
                }, 
                "investigator": [
                    {
                        "last_name": "Silvania CV Archangelo, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Antonio Marcos C Francisco, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Fabiola S Campos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Pouso Alegre", 
                        "country": "Brazil", 
                        "state": "Minas Gerais", 
                        "zip": "37550-000"
                    }, 
                    "name": "Hospital e Maternidade Santa Paula"
                }, 
                "investigator": {
                    "last_name": "Fabiola S Campos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Antibiotic Prophylaxis in Gynecologic Laparoscopy", 
        "overall_contact": {
            "email": "fabiolasmc@gmail.com", 
            "last_name": "Fabiola SM Campos, MD", 
            "phone": "553534235988"
        }, 
        "overall_official": [
            {
                "affiliation": "Universidade do Vale do Sapucai", 
                "last_name": "Fabiola SM Campos, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universidade do Vale do Sapucai", 
                "last_name": "Daniela F Veiga, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients are followed weekly by a masked surgeon in regard to surgical site infecton (SSI), until the 30th postoperative day. Centers for Disease Control and Prevention's (CDC) criteria and classification were adopted.", 
            "measure": "Surgical site infection", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991834"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universidade do Vale do Sapucai", 
            "investigator_full_name": "Fabiola Soares Moreira Campos", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Universidade do Vale do Sapucai", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universidade do Vale do Sapucai", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}